Expert lecture
Home > Expert lecture > Content Pages
 
How Molecular Diagnosis Affects the Management of Early Stage CRC
2016-01-12
 
 

Peter Lenehan, MD PhD is Chief Medical Officer at Everist Genomics, Inc. (Ann Arbor, MI), a biotechnology company that has been successful in developing and commercializing multiple products in cancer genomics and cardiovascular risk assessment. Prior to joining Everist Genomics in 2005, Peter was Director of Clinical Oncology at Pfizer, where he coordinated the international clinical development of multiple small-molecule tyrosine kinase inhibitors, and before that, was on faculty at the University of Maryland School of Medicine. Peter received his basic research and clinical training at the Sloan Kettering Institute for Cancer Research, the State University of New York, Thomas Jefferson University, and the University of Maryland.   

Date: June 28th, 2014       Time: 9:00am EST (USA)

“How Molecular Diagnosis Affects the Management of Early Stage CRC”

 
>> Returns a list of pages
 
Related Category
Promotion Products
More
 
 
  • Partners
  • Links
USCAP  |   CAP  |   IAP  |   TPIS  |   ASC  |   CAP-ACP  |   ASIP  |   AMP  |   ASCP  |   CAPA  |  
Home  |  News  |  Journals  |  Cases  |  Lectures  |  Experts  |  Telepath  |  Research  |  Conferences  |  Job_Position  |  Books  |  Sponsors
2009-2015 All Rights Reserved GoPath Diagnostics, LLC.